CINCINNATI, Aug. 22, 2016 /PRNewswire/ -- BioRx, a Diplomat company (NYSE: DPLO), announced today the release of its newest version of the MyFactor® app for iOS and Android mobile devices. The new versions of the app are available for download on the App Store and Google Play.
MyFactor® enables hemophilia patients to record bleeding episodes and treatments, and facilitates easy sharing of information with their health care team, including caregivers, physicians, pharmacists and nurses.
The new version provides cloud-based data storage and synchronization across multiple mobile devices, allowing caregivers to view multiple patients' data on a single device. "Unlike most hemophilia apps available on the market, MyFactor® now provides the confidence of secure cloud-based data storage," said Eric Hill, vice president, chief operating officer of Diplomat Specialty Infusion Group. "As users increasingly upgrade, add or change mobile devices, safeguarding the continuity of their data becomes imperative. The new MyFactor® ensures users can access their data on any device that runs the app."
While the new iOS app effectively replaces the original iOS release in 2013, the original app remains available on the App Store, renamed "MyFactor® Classic." It has been updated to include a "data export" feature (available in the app's "Profile" section). This feature allows users of the original iOS app to migrate their data to the new app and, with the addition of an email address, benefit from secure, cloud-based data storage. MyFactor® Classic will remain on the App Store for an undetermined period to allow time for users to convert. Apple iOS users can find instructions for exporting their data to the new version at biorxhemophilia.com/myfactor. Users of the current Android app simply need to download the update from Google Play and add their email address in the profile section to enable cloud-based data backup.
"We are excited to release this innovative app as a way to better support our patients with hemophilia or any other related bleeding disorders," said Diplomat CEO and Chairman Phil Hagerman. "This platform allows a revolutionary way for patients to stay on track with their treatment and share information with members of their health care team."
BioRx was acquired by Diplomat in 2015. To learn more about the company, visit biorx.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management's good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat's filings with the Securities and Exchange Commission, including "Risk Factors" in Diplomat's Annual Report on Form 10-K for the year ended December 31, 2015 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
BioRx, a Diplomat company, is a highly specialized pharmacy and infusion services provider that provides treatments for patients with ultra-orphan and rare, chronic diseases. In addition to pharmacy and infusion services, BioRx also serves health plans and payor organizations with comprehensive data analytics and therapy reporting. The company's clinical staff reaches patients in all 50 states and operates dispensing facilities in Ohio, Massachusetts, North Carolina, Iowa, Minnesota, Arizona and California. To learn more, visit www.biorx.com.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: "Take good care of patients and the rest falls into place." Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit diplomat.is.